Myriad Genetics, Inc. (MYGN): Price and Financial Metrics


Myriad Genetics, Inc. (MYGN): $30.49

0.28 (+0.93%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MYGN Stock Summary

  • Over the past twelve months, MYGN has reported earnings growth of 2,169.9%, putting it ahead of 99.36% of US stocks in our set.
  • As for revenue growth, note that MYGN's revenue has grown -28.45% over the past 12 months; that beats the revenue growth of just 12.53% of US companies in our set.
  • The volatility of Myriad Genetics Inc's share price is greater than that of 83.67% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to MYGN, based on their financial statements, market capitalization, and price volatility, are LIQT, ITMR, LNDC, DRTT, and ISDR.
  • Visit MYGN's SEC page to see the company's official filings. To visit the company's web site, go to myriad.com.

MYGN Stock Price Chart Interactive Chart >

Price chart for MYGN

MYGN Price/Volume Stats

Current price $30.49 52-week high $31.60
Prev. close $30.21 52-week low $9.24
Day low $29.41 Volume 944,600
Day high $31.05 Avg. volume 915,305
50-day MA $25.39 Dividend yield N/A
200-day MA $16.80 Market Cap 2.29B

Myriad Genetics, Inc. (MYGN) Company Bio


Myriad Genetics discovers and commercializes molecular diagnostic tests that; determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties to improve patient care. The company was founded in 1991 and is based in Salt Lake City, Utah.


MYGN Latest News Stream


Event/Time News Detail
Loading, please wait...

MYGN Latest Social Stream


Loading social stream, please wait...

View Full MYGN Social Stream

Latest MYGN News From Around the Web

Below are the latest news stories about Myriad Genetics Inc that investors may wish to consider to help them evaluate MYGN as an investment opportunity.

Myriad Genetics, Inc. (MYGN) CEO Paul Diaz on Q2 2021 Results - Earnings Call Transcript

Myriad Genetics, Inc. (MYGN) Q2 2021 Earnings Conference Call February 23, 2021 04:30 PM ET Company Participants Scott Gleason - Senior Vice President of Investor Relations and Corporate Strategy Paul Diaz - President and Chief Executive Officer Bryan Riggsbee - Chief Financial Officer Conference Call Participants Doug Schenkel - Cowen...

SA Transcripts on Seeking Alpha | February 24, 2021

Recap: Myriad Genetics Q2 Earnings

Shares of Myriad Genetics (NASDAQ:MYGN) were unchanged in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 152.17% over the past year to ($0.12), which were in line with the estimate of ($0.12). Revenue of $154,600,000 declined by 20.76% from the same period last year, which beat the estimate of $150,390,000. Guidance Earnings guidance hasn't been issued by the company for now. Myriad Genetics hasn't issued any revenue guidance for the time being. How To Listen To The Conference Call Date: Feb 23, 2021 View more earnings on MYGN Time: 04:30 PM ET Webcast URL: https://edge.media-server.com/mmc/p/qfo34i6u Recent Stock Performance Company's 52-week high was at $31.59 52-week low: $9.24 Price action over last quarter: Up 69.96% Compa...

Yahoo | February 23, 2021

Myriad Genetics Delivers 6% Sequential Revenue Growth; Company Continues to Execute Strategic Transformation Plan

Highlights: Revenue of $154.6 million up 6% sequentially in quarter ended Dec. 31, 2020GAAP Earnings per share (EPS) of ($0.59) and adjusted EPS of ($0.12) Despite COVID-19 headwinds, total test volumes increase 7% sequentially with stable pricingSigned in-network agreement with the majority of Anthem Blue Cross Blue Shield health plans, the second largest commercial payer in the United States, returning all Myriad products to in-network status Paul J. Diaz, President and Chief Executive Officer:“In the midst of the COVID-19 pandemic, we continued to support our patients and healthcare providers with critical genetic insights needed to drive better health outcomes. This quarter we continued to see sequential improvement in test volumes and revenue trends, while executing on our strategi...

Yahoo | February 23, 2021

Myriad Genetics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 23, 2021 / Myriad Genetics, Inc. (NASDAQ:MYGN) will be discussing their earnings results in their 2021 Second Quarter Earnings call to be held on February 23, 2021 at 4:30 PM Eastern Time.

Yahoo | February 23, 2021

A Preview Of Myriad Genetics's Earnings

Myriad Genetics (NASDAQ:MYGN) will be releasing its next round of earnings this Tuesday, February 23. For all of the relevant information, here is your guide for Tuesday's Q2 earnings announcement. Net Income, Earnings, And Earnings Per Share Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS. Earnings And Revenue Myriad Genetics EPS loss is expected to be around $0.12, according to sell-side analysts. Sales will likely be near $150.39 million. Myriad Genetics EPS in the same period a year ago totaled $0.23. Revenue was $195.10 million. What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter? Wall Street ana...

Yahoo | February 22, 2021

Read More 'MYGN' Stories Here

MYGN Price Returns

1-mo 10.67%
3-mo 73.83%
6-mo 122.55%
1-year 73.04%
3-year -4.12%
5-year -14.23%
YTD 54.18%
2020 -27.38%
2019 -6.33%
2018 -15.36%
2017 106.03%
2016 -61.38%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.0556 seconds.